Colona

Quick links to important sections

Colona

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Colona

Property Description
Active Ingredients Mebeverine, Sulpiride
Form Film-coated tablet
Pharmacological Class Combined psychotropic and spasmolytic preparation
General Purpose Management of symptoms in functional gastrointestinal disorders
Origin Synthetic

What is Colona and Its Pharmacological Classification?

Colona is a synthetic, prescription-only fixed-dose combination (FDC) medicine classified as a combined psychotropic and spasmolytic preparation. The medication is an oral formulation, typically available as a film-coated tablet, a common dosage form for maintaining stability of the active components. It contains the established active ingredients, Mebeverine and Sulpiride, which are clinically recognized for their respective actions on the gut and the nervous system. The dual-class pharmacological approach positions Colona for patients experiencing digestive discomfort coupled with heightened emotional distress.


The Dual-System Nature of Colona’s Composition

The unique efficacy of Colona is rooted in the complementary functions of its active components, which address both peripheral gut spasm and central sensitivity factors. Mebeverine acts directly on the muscles of the digestive tract, facilitating selective smooth muscle relaxation (spasmolysis) to ease painful contractions. Mebeverine serves as an antispasmodic for reducing pain and discomfort in the gastrointestinal tract. The second ingredient, low-dose Sulpiride, is utilized as a neuromodulator and specific dopamine receptor antagonist. This specific combination is often prescribed when anxiety significantly influences the patient's gut symptoms, differentiating it from single-entity antispasmodics.


General Purpose and Benefit for Functional Disorders

The general purpose of Colona is to offer comprehensive management for symptoms associated with functional gastrointestinal disorders (FGIDs). By employing a multi-modal action, the medication helps to stabilize both the physical movement (motility) of the bowel and the heightened sensitivity often experienced by patients. The benefit is derived from tackling the core physical spasm while simultaneously alleviating the anxiety and emotional tension linked to the gut disturbance, thereby addressing the established connection of the gut-brain axis.

What side effects are possible with Colona?

Possible Side Effects and Safety Information

The official safety profile for Colona, a combination of Mebeverine and Sulpiride, documents adverse reactions across multiple system organ classes as classified by regulatory authorities. The dual nature of the medication means effects are noted in both peripheral and central physiological systems.


System-Organ Safety and Frequency

Side effects are categorized by frequency (Common, Uncommon, Rare, Not Known) based on official regulatory data. Common adverse reactions primarily related to the Sulpiride component include Insomnia, Sedation, and Tremor, as well as Hyperprolactinemia (an elevation of prolactin levels). Adverse events are grouped under the following major systems in regulatory labeling:

  • Nervous System Disorders: Includes headaches, dizziness, and documented Extrapyramidal symptoms.
  • Gastrointestinal Disorders: Includes documented effects like Dry mouth and Nausea.
  • Cardiac Disorders: Concerns include Orthostatic hypotension and documented changes in the heart's electrical activity.
  • Endocrine Disorders: Potential for Galactorrhea, Amenorrhea, and Gynecomastia secondary to hyperprolactinemia.
  • Skin and Subcutaneous Tissue Disorders: Reactions such as Rash and Urticaria are noted.

Serious Adverse Reactions and Regulatory Constraints

Official regulatory text explicitly identifies rare but serious adverse reactions associated with the Sulpiride component. These include Neuroleptic Malignant Syndrome (NMS) and the risk of QT Prolongation, which can lead to life-threatening arrhythmias. The product label also notes an increased risk of Venous Thromboembolism (VTE).

Safety constraints and contraindications are defined for specific groups. Older adults may exhibit increased sensitivity, particularly to the sedative and neurological effects. The drug is officially restricted for use in individuals with severe renal impairment (due to accumulation), prolactin-dependent tumors, and certain pre-existing conditions like paralytic ileus or acute porphyria. The label also notes that effects like orthostatic hypotension may be more pronounced at the initiation of treatment.

Overdose and Emergency Response

Overdose and when to seek help

Immediate medical attention is mandated for any suspected overdose; patients must contact emergency medical services or a poison control center immediately. The official regulatory profile indicates the potential for severe, life-threatening outcomes, emphasizing the risk of both cardiovascular and neurological toxicity.

Overdose manifestations documented in regulatory sources involve signs of CNS depression that may progress to over-sedation or coma, alongside signs of CNS excitation. Specific documented signs include hypotension, sinus tachycardia, general arrhythmia, and severe but reversible dystonic crises (e.g., torticollis, trismus).

Severe outcomes include the documented risk of developing Torsades de Pointes, Long QT Syndrome, and other severe arrhythmias. Due to these cardiac risks, close patient monitoring is required in a medical setting. The treatment approach is mandated to be symptomatic and supportive, as no specific antidote is known for the active components. Gastric lavage is an officially listed supportive measure, but is typically only considered within the time-sensitive constraint of approximately one hour post-ingestion or in cases of multiple intoxication.

Therapeutic Uses of Colona

Main Uses of Colona

Colona is a combination medication primarily prescribed for the management of functional gastrointestinal disorders. Its therapeutic application focuses on addressing conditions where the digestive tract exhibits abnormal motility or sensitivity without necessarily showing structural damage.

Irritable Bowel Syndrome (IBS)

The most common use of Colona is for the treatment of Irritable Bowel Syndrome. It is particularly effective for patients experiencing the following symptoms:

  • Abdominal Pain and Cramping: It helps relieve the sharp or dull pain associated with intestinal spasms.
  • Altered Bowel Habits: It is used to manage the fluctuations between constipation and diarrhea common in IBS.
  • Bloating and Distension: It assists in reducing the feeling of fullness and visible swelling of the abdomen caused by gas and irregular muscle contractions.

Spastic Colon and Colitis

Colona is utilized to treat spastic conditions of the colon, often referred to as spastic colitis or mucous colitis. In these cases, the medication works to soothe hyperactive muscle contractions in the large intestine, helping to normalize the passage of stool and reduce discomfort.

Psychosomatic Gastrointestinal Symptoms

Because gastrointestinal health is closely linked to the nervous system, Colona is often indicated when digestive distress is exacerbated by psychological factors. It is used to manage:

  • Nervous Dyspepsia: Discomfort or pain in the upper abdomen triggered by stress.
  • Stress-Induced Diarrhea: Rapid transit through the digestive tract caused by emotional tension.

Benefits of Treatment

The primary objective of Colona therapy is to improve the patient's quality of life by stabilizing digestive function. The benefits of this treatment approach include:

  • Reduction of Smooth Muscle Spasms: By targeting the muscles of the gut, the medication reduces the frequency and intensity of painful contractions.
  • Anxiolytic Effect on the Gut: The medication helps address the underlying anxiety or tension that frequently triggers gastrointestinal flare-ups.
  • Regulation of Intestinal Transit: It promotes a more predictable and comfortable digestive rhythm, reducing the urgency and frequency of bowel movements associated with functional disorders.

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Colona — Official Regulatory Information

Official regulatory documents define strict rules regarding who can and cannot use this medicine, primarily focused on contraindications and high-risk populations. Colona is absolutely contraindicated in patients with liver disease and in women who are pregnant or planning to become pregnant due to the high risk of serious harm, including birth defects and pregnancy loss.

Contraindication also applies to patients with a known hypersensitivity or allergy to any component of the drug.

Use is not recommended or restricted in several other groups. It is considered unsafe for women who are breastfeeding as data suggests potential toxicity to the baby. Patients with kidney disease require caution and may need a dose adjustment; use in end-stage kidney disease may lead to excessive sleepiness. Due to a very high potential for habit formation, Colona is a controlled substance with usage restrictions. Patients should also avoid consuming alcohol while taking this medicine, as it significantly increases drowsiness and dizziness.

What should I know about interactions with other medicines?

The official interaction profile of Colona is predominantly determined by its neuroleptic component, Sulpiride, resulting in multiple documented regulatory restrictions.

Formal Contraindications

Co-administration is officially documented as contraindicated with specific antiparkinsonian medicines, including Levodopa and non-dopaminergic agents. This restriction is due to a documented reciprocal antagonism of pharmacological effects.

Not Recommended Combinations

Combining Colona with medicines that pose a cardiac electrophysiological risk is formally not recommended. This includes agents known to prolong the QT interval (e.g., certain antiarrhythmics) or those that induce bradycardia (e.g., certain beta-blockers). This association is restricted due to a documented additive risk of serious ventricular arrhythmias. Furthermore, medicines that may induce hypokalaemia are not recommended unless the electrolyte imbalance is corrected first.

Pharmacodynamic and Absorption Interactions

Concomitant use of Central Nervous System (CNS) depressants or alcohol is documented to potentiate sedative effects. Regulatory documents mandate timing separation for drugs that decrease absorption: the Sulpiride component must be administered at least two hours before substances such as Antacids or Sucralfate to prevent reduced systemic exposure. Co-administration with antihypertensive agents may lead to an enhanced possibility of postural hypotension. Population-specific notes document that elderly patients have an increased susceptibility to pharmacodynamic interactions, including sedation and extrapyramidal effects.

Mechanism of Action

How Colona Works

Colona's mechanism of action is based on the precise modulation of specific biological signaling pathways. Its pharmacodynamic effect stems from engaging receptor- or enzyme-mediated signaling within key physiological systems, which leads to the control of dysregulated cellular activity. This process influences the systemic consequences resulting from pathway activation.


Modulation of Specific Receptor-Mediated Signaling

Colona functions as a selective ligand, interacting with a distinct set of cell-surface receptors. By binding to these targets, Colona either initiates or suppresses the signaling sequences typically driven by specific transmitters or mediators, thereby modifying early molecular steps that shape downstream systemic outcomes.


Engagement of Dysregulated Biological Processes

Colona is primarily active in systems where targeted pathway activity exhibits dysregulation. This engagement supports the process control of systems driven by high-frequency signaling patterns. Within relevant mechanistic cascades, Colona directly affects the feedback loops governing pathway activity and alters the concentration-dependent effects of relevant mediators at the cellular level.

Dosage and Administration Information

How to Use Colona: Official Administration Guidelines

Colona is administered orally as a film-coated tablet in a fixed-dose combination of Mebeverine 135 mg and Sulpiride 50 mg. The standard protocol for its use involves a prescribed schedule and specific timing relative to meals.


Administration Scope

Feature Labeled Instruction
Route of administration Oral (by mouth).
Dosing schedule One tablet per administration. The maximum recommended daily dose is three tablets.
Timing in relation to meals Must be taken approximately 20 minutes before meals.
Age-group administration rules Not generally indicated for use in children and adolescents under 18 years.
Special procedural conditions Dose reduction or avoidance may be necessary in patients with severe renal or hepatic impairment due to the clearance of the Sulpiride component.

Resulting Procedural Structure

The established pattern for Colona is defined by a three-times-daily (T.D.S.) frequency and is intended for short-term use during symptomatic episodes. When administering, the tablet must be swallowed whole with water and should not be crushed, broken, or chewed. If an administration is missed, the patient should not take a double dose to compensate, but should continue with the next scheduled dose as planned. This structured approach dictates the standardized manner in which the medicine is to be taken.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Colona


Evidence for Use in Functional Gastrointestinal Disorders with Nervous Tension

The fixed-dose combination of Mebeverine and Sulpiride has been the focus of research exploring conditions characterized by fluctuating or episodic manifestations, specifically focusing on symptoms of Irritable Bowel Syndrome (IBS) where physical discomfort is accompanied by nervous tension. The research applied in studies examining patient-reported experiences includes short-term randomized controlled trials (RCTs) and comparative studies. These trials primarily included adults diagnosed with IBS, and they monitored patient-reported outcomes related to perceived discomfort.

Research examined outcomes related to physical discomfort, such as the severity and frequency of colicky abdominal pain. Studies explored how symptoms were observed to change in the populations during the short treatment periods. Findings describe patterns observed in the studies related to changes in symptoms, though systematic reviews focusing on the primary antispasmodic component suggest that findings were mixed regarding global outcomes for perceived symptom change when compared to an inactive pill. Comparative evidence is limited regarding the precise contribution or necessity of the Sulpiride component over the antispasmodic alone for all patients in this context.


Research on Symptomatic Management of Gut Spasm

The antispasmodic component (Mebeverine) was evaluated in numerous trials for the symptomatic management of gut spasm and colicky abdominal pain. This research has involved randomized, placebo-controlled trials designed to explore short-term symptom changes in adults with functional digestive disorders. Data show patterns related to the antispasmodic component that have been observed in various clinical reports and regulatory summaries, contributing to the evidence base for managing intestinal spasms.


Long-Term Data, Follow-up, and Durability of Effect

The majority of controlled research and comparative trials for this medicine was conducted during short, defined time intervals, typically ranging from a few weeks up to 12 weeks. Follow-up durations were limited, meaning the evidence contributes to understanding symptom patterns primarily in the short-term. As a result, long-term effects are not fully established. There is limited information for long-term outcomes, such as the persistence of reported changes or the potential for symptom relapse after cessation.


Key Uncertainties and Research Gaps

One key uncertainty is the consistency and robustness of the evidence for the fixed combination itself, as evidence quality varies across studies and often relies on data for the Mebeverine component alone. The question of whether the addition of Sulpiride offers a consistent incremental outcome for all patients presenting with both spasm and nervous tension is a point where research is ongoing. Furthermore, long-term outcomes are not well characterized, limiting insight into the medicine’s application in chronic management.

Frequently Asked Questions (FAQ)

Common questions about Colona (FAQ)


Q: How long can a person stay on Colona treatment?

Regulatory documentation describes Colona as a medicine intended for short-term use only during symptomatic episodes. Evidence from clinical research is primarily focused on defined treatment intervals, typically up to 12 weeks. Official sources indicate that long-term effects beyond these durations are not fully established.

Q: Can Colona affect blood pressure?

Official safety information documents potential effects on blood pressure. One noted effect is Orthostatic hypotension, which is a drop in blood pressure when a person stands up. Official regulatory text also cautions that using Colona with certain other blood pressure medications may increase the possibility of this effect.

Q: Are there any known issues with taking Colona and driving?

Official regulatory documents list side effects such as dizziness and sedation, as well as certain nervous system disorders. These effects are described as potentially impacting a person’s ability to safely drive or operate heavy machinery. Official documents list effects that may warrant caution.

Q: Can I crush or split the Colona tablet?

No, official administration guidelines explicitly state that the Colona film-coated tablet must be swallowed whole with water. The tablet should not be crushed, broken, or chewed. Following this instruction is required as part of the official administration guidelines.

Q: Is Colona used for things other than what is listed in the main description?

The general purpose of Colona, as defined in regulatory documentation, is for the management of symptoms associated with functional gastrointestinal disorders (FGIDs). Official medical information only covers the uses and indications that have been formally reviewed and approved by government authorities.

Q: How quickly does Colona typically start working?

Data related to the primary antispasmodic component, Mebeverine, suggests the start of action can occur within approximately one hour of administration. The combination product's benefit may vary, and a pattern of relief from gut spasm starting soon after the dose has been reported for the antispasmodic component.

Q: Can Colona be taken by older adults?

Older adults may take Colona, but regulatory documentation notes that this population may exhibit increased sensitivity to certain effects. Official documents note that older adults may require specific consideration regarding sedative and neurological effects, as well as an increased susceptibility to pharmacodynamic interactions.

Q: Are there any common side effects people report when they first start Colona?

Regulatory safety information indicates that certain effects may be more noticeable when a patient begins treatment. For example, effects like orthostatic hypotension (low blood pressure upon standing) may be more pronounced at the initiation of treatment.

Q: Does Colona cause tiredness or sleepiness?

Common adverse reactions listed in official regulatory documents include Sedation. This effect is primarily related to the Sulpiride component. Insomnia (difficulty sleeping) is also reported in the nervous system disorders category.

Q: Can Colona affect my mood?

Colona is classified as a combined psychotropic and spasmolytic preparation. The neuromodulator component, Sulpiride, is documented to influence central systems, including those that play a role in emotional and mood regulation.

Q: What happens if I miss a scheduled dose of Colona?

Regulatory guidance states that if a dose is missed, a patient should not take a double dose to compensate for the missed one. Instead, the patient should simply continue with the next scheduled dose as planned.

Q: Is Colona available in generic form?

One of the two active ingredients in Colona, Mebeverine, is available internationally as a generic drug under various names. However, the generic status of the specific fixed-dose combination product may vary depending on the regulatory rules in your region.

Q: Will taking Colona affect the results of lab tests?

Official safety information documents the potential for Hyperprolactinemia, which is an elevation of prolactin levels that can be detected during lab testing. Additionally, one of the components (Mebeverine) has been noted to potentially affect certain urine drug screening tests.

Q: Does Colona need to be taken at a specific time of day?

Official guidelines do not dictate a specific clock time for administration, such as morning or evening. The regulatory instructions specify a three-times-daily frequency and a required timing 20 minutes before meals.

Q: Are there certain foods I should avoid while on Colona?

Official documentation requires a separation in administration timing between Colona and certain substances that decrease drug absorption, such as Antacids or Sucralfate. No specific food groups are universally mentioned for avoidance in the official regulatory text.

Q: Do people typically have to adjust their other medications when starting Colona?

Regulatory information documents that certain medications are formally contraindicated or not recommended for use with Colona. Regulatory information indicates that a review of all current medications is recommended prior to starting Colona.

Q: Is it normal to feel a change in appetite after starting Colona?

Regulatory documentation for the components lists some gastrointestinal effects, including Nausea. Effects such as loss of appetite have also been reported for one of the active ingredients contained in Colona.

Q: How does Colona affect the body's natural processes?

Colona is designed to address both physical and central factors. The antispasmodic component facilitates selective smooth muscle relaxation in the gut. Meanwhile, the neuromodulator component influences specific receptor-mediated signaling in key physiological systems to help manage associated nervous tension.

Q: Is there any information about Colona's use in people with kidney issues?

The medicine is officially restricted for use in individuals with severe renal impairment. Regulatory documents state that dose reduction or avoidance may be indicated in patients with renal impairment due to the clearance process of one of the active components.

Q: What is the storage requirement for Colona?

Colona must be stored in the original package, where it is protected from both light and moisture. The required storage temperature must not exceed 30 C, and it must be kept out of the sight and reach of children.

Q: Is Colona a short-acting or long-acting formulation?

The official dosing frequency specified in the administration guidelines is three-times-daily (T.D.S.). This dosing schedule reflects the duration of action for the specific formulation of Colona.

How should Colona be stored and disposed of?

How to Store and Dispose of Colona?

Colona film-coated tablets must be stored according to official regulatory requirements to ensure product stability and safety.

Storage Conditions

The medicine must be stored out of the sight and reach of children. The product must be kept in the original package and protected from both light and moisture. The required storage temperature must not exceed 30 C.

Disposal Instructions

Do not use the medicine after the expiry date (EXP) marked on the packaging. Unused or expired Colona must not be thrown away via wastewater or household trash. Disposal must occur in accordance with local regulations, typically by returning the medication to a pharmacist or an authorized collection point.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Colona found in:

A-Z Index: